Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RBS2418 |
Synonyms | |
Therapy Description |
RBS2418 inhibits ENPP1, which results in decreased adenosine levels and potentially results in enhanced antitumor immune response (J Clin Oncol 40, no. 16_suppl (June 01, 2022) e14550). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RBS2418 | RBS 2418|RBS-2418 | RBS2418 inhibits ENPP1, which results in decreased adenosine levels and potentially results in enhanced antitumor immune response (J Clin Oncol 40, no. 16_suppl (June 01, 2022) e14550). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05270213 | Phase I | RBS2418 | RBS2418 Evaluation in Subjects With Unresectable or Metastatic Tumors | Recruiting | USA | 0 |